BridgeBio Pharma Revenue 2018-2024 | BBIO
BridgeBio Pharma revenue from 2018 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
BridgeBio Pharma Annual Revenue
(Millions of US $) |
| 2023 |
$9 |
| 2022 |
$78 |
| 2021 |
$70 |
| 2020 |
$8 |
| 2019 |
$41 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$3 |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$211 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$74 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$2 |
| 2021-06-30 |
$54 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$14 |
| 2019-09-30 |
$27 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.953B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
